您当前所在的位置:首页 > 产品中心 > 产品详细信息
115103-54-3 分子结构
点击图片或这里关闭

(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid

ChemBase编号:782
分子式:C20H25NO2S2
平均质量:375.548
单一同位素质量:375.13267105
SMILES和InChIs

SMILES:
s1c(/C(=C\CCN2C[C@@H](CCC2)C(=O)O)/c2sccc2C)c(cc1)C
Canonical SMILES:
OC(=O)[C@@H]1CCCN(C1)CC/C=C(\c1sccc1C)/c1sccc1C
InChI:
InChI=1S/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)/t16-/m1/s1
InChIKey:
PBJUNZJWGZTSKL-MRXNPFEDSA-N

引用这个纪录

CBID:782 http://www.chembase.cn/molecule-782.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid
IUPAC传统名
tiagabine
商标名
Gabitril
别名
Tiagabina [INN-Spanish]
Tiagabinum [INN-Latin]
Tiagabine
CAS号
115103-54-3
PubChem SID
160964245
46505560
PubChem CID
60648

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID
DrugBank DB00906 external link
PubChem 60648 external link
数据来源 数据ID 价格

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 4.1433096  质子受体
质子供体 LogD (pH = 5.5) 2.5883915 
LogD (pH = 7.4) 2.59872  Log P 2.6014485 
摩尔折射率 115.3171 cm3 极化性 40.297897 Å3
极化表面积 40.54 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P 4.98  LOG S -4.25 
溶解度 2.11e-02 g/l 

分子性质

分子性质

理化性质 生物活性(PubChem)
疏水性(logP)
2.6 expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank
DrugBank -  DB00906 external link
Item Information
Drug Groups approved
Description Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
Indication For the treatment of partial seizures
Pharmacology Tiagabine is used primarily as an anticonvulsant for the adjunctive treatment of epilepsy. The precise mechanism by which Tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Tiagabine binds to recognition sites associated with the GABA uptake carrier. It is thought that, by this action, Tiagabine blocks GABA uptake into presynaptic neurons, permitting more GABA to be available for receptor binding on the surfaces of post-synaptic cells.
Toxicity mptoms most often accompanying tiagabine overdose, alone or in combination with other drugs, have included: seizures including status epilepticus in patients with and without underlying seizure disorders, nonconvulsive status epilepticus, coma, ataxia, confusion, somnolence, drowsiness, impaired speech, agitation, lethargy, myoclonus, spike wave stupor, tremors, disorientation, vomiting, hostility, and temporary paralysis. Respiratory depression was seen in a number of patients, including children, in the context of seizures.
Affected Organisms
Humans and other mammals
Biotransformation Tiagabine is likely metabolized primarily by the 3A isoform subfamily of hepatic cytochrome P450.
Absorption Tiagabine is nearly completely absorbed (>95%).
Half Life 7-9 hours
Protein Binding 96%
Elimination Approximately 2% of an oral dose of tiagabine is excreted unchanged, with 25% and 63% of the remaining dose excreted into the urine and feces, respectively, primarily as metabolites.
Clearance * 109 mL/min [Healthy subjects]
External Links
Wikipedia
RxList
Drugs.com

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
    暂无数据
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle